Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of 36,831 restricted stock units to 21 newly hired non-executive officers. The awards were approved by the company's compensation committee and issued under the Ultragenyx Employment Inducement Plan on April 16, 2025.
The stock units feature a four-year vesting schedule, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement for new hires.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha annunciato la concessione di 36.831 unità di azioni vincolate a 21 nuovi dirigenti non esecutivi. I premi sono stati approvati dal comitato per le retribuzioni della società e assegnati nell'ambito del Piano di Incentivazione all'Assunzione di Ultragenyx il 16 aprile 2025.
Le unità azionarie prevedono un piano di maturazione quadriennale, con il 25% delle azioni che matura ogni anno nell'anniversario della data di assegnazione, subordinatamente alla continuità del rapporto di lavoro. Questa concessione è stata effettuata in conformità alla Regola 5635(c)(4) del Nasdaq come incentivo all'assunzione per i nuovi dipendenti.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha anunciado la concesión de 36.831 unidades restringidas de acciones a 21 nuevos oficiales no ejecutivos contratados recientemente. Los premios fueron aprobados por el comité de compensación de la empresa y otorgados bajo el Plan de Incentivos por Contratación de Ultragenyx el 16 de abril de 2025.
Las unidades de acciones cuentan con un programa de adquisición de derechos de cuatro años, con el 25% de las acciones que se adquieren anualmente en el aniversario de la fecha de concesión, condicionado a la continuidad del empleo. Esta concesión se realizó conforme a la Regla 5635(c)(4) de Nasdaq como un incentivo laboral para nuevas contrataciones.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 21명의 신임 비임원 임원들에게 36,831개의 제한 주식 단위를 부여했다고 발표했습니다. 이 상은 회사의 보상 위원회에서 승인되었으며, 2025년 4월 16일 Ultragenyx 채용 유인 계획에 따라 발행되었습니다.
주식 단위는 4년간의 권리 취득 일정을 특징으로 하며, 매년 부여일 기념일에 25%의 주식이 계속 고용 조건 하에 취득됩니다. 이 부여는 신규 채용에 대한 고용 유인책으로서 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Ultragenyx Pharmaceutical (NASDAQ : RARE) a annoncé l’attribution de 36 831 unités d’actions restreintes à 21 nouveaux cadres non exécutifs récemment embauchés. Les attributions ont été approuvées par le comité de rémunération de l’entreprise et émises dans le cadre du plan d’incitation à l’emploi d’Ultragenyx le 16 avril 2025.
Ces unités d’actions bénéficient d’un calendrier d’acquisition sur quatre ans, avec 25 % des actions acquises chaque année à la date anniversaire de l’attribution, sous réserve de la continuité de l’emploi. Cette attribution a été réalisée conformément à la règle 5635(c)(4) du Nasdaq en tant qu’incitation à l’embauche.
Ultragenyx Pharmaceutical (NASDAQ: RARE) hat die Gewährung von 36.831 Restricted Stock Units an 21 neu eingestellte nicht-exekutive Führungskräfte bekannt gegeben. Die Auszeichnungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und am 16. April 2025 im Rahmen des Ultragenyx Employment Inducement Plans ausgegeben.
Die Aktienanteile unterliegen einem vierjährigen Vesting-Zeitplan, wobei jährlich 25 % der Aktien am Jahrestag der Gewährung freigegeben werden, vorausgesetzt, dass das Arbeitsverhältnis fortbesteht. Diese Gewährung erfolgte gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für Neueinstellungen.
- None.
- None.
NOVATO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 36,831 restricted stock units of the company’s common stock to 21 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant to new employees in April 2025?
What is the vesting schedule for Ultragenyx's (RARE) April 2025 restricted stock units?
Under which plan were Ultragenyx's (RARE) April 2025 stock grants issued?
When did Ultragenyx (RARE) approve the April 2025 restricted stock unit grants?
